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INTRODUCTION
Background
The development of a new drug takes a lot of cost and time. The expenses can be dramatically reduced if the in-vivo performance of drug formulation can be predicted by in-vitro behavior [35] . In-vitro, which means "within the glass" in Latin, refers to the method of running an experiment on cells or biological molecules outside of a living organism in a controlled environment such as cells in an artificial culture medium. On the other hand, in-vivo, which means "within the living" in Latin, refers to performing an experiment on a whole, living organism such as animal studies and clinical trials [37] .
IVIVC
An in-vitro in-vivo correlation (IVIVC) has been defined by the U.S. Food and Drug Administration (FDA) as "a predictive mathematical model describing the relationship between an in vitro property of an extended release dosage form (usually the rate or extent of drug dissolution or release) and a relevant in vivo response, e.g., plasma drug concentration or amount of drug absorbed" [1] . The United States Pharmacopeia (USP) refers to the term in vitro-in vivo correlation as "the establishment of a rational relationship between a biological property, or a parameter derived from a biological property produced by a dosage form, and a physicochemical property or characteristic of the same dosage form" [2] . In-vitro in-vivo correlation (IVIVC) has a significant effect on pharmaceutical development of dosage forms due to its application as a surrogate for in-vivo bioavailability and supporting biowaivers. Since a bioequivalence study is needed to validate a new formulation, which takes a lot of time and money, and as asserted before, time and money are always significant issues. Therefore, in pharmaceutical studies, the application of IVIVC is very important [3] .
In order to develop an IVIVC, the observed fraction of the drug absorbed (in-vivo) and that of the drug dissolved (in-vitro) are needed. The observed fraction of the drug absorbed can be obtained using the numerical deconvolution method which then will be correlated with in-vitro dissolution data. Performing the deconvolution needs a reference product. The reference product can be an immediate release product or an intravenous solution [1] , which in Cheng's et al. [3] According to Cheng et al. [3] , the IVIVC refers to the relationship between in-vitro dissolution profiles of propranolol hydrochloride from different release rates formulations extended-release tablet ER-F (fast rate of release) and ER-S (slow rate of release) and invivo cumulative percentage absorption rate of the same tablets calculated by using the numerical deconvolution approach. One issue about IVIVCs is that they are usually developed in the fasted state [1] , like the in-vivo absorption studies performed in the study by Cheng et al. [3] study. In that study, all of the six male Beagle dogs were fasted for twelve hours before the experiment, and they just had access to unlimited water. In some studies, performing the experiment in the fasted state was not possible, thus they try a fed state [1] . Another issue is that in order to obtain the dissolution characteristics of the ER dosage form, the same method should be used for all formulations. In Cheng et al. [3] study, the release characteristic of all the propranolol extended-release tablets were determined using USP apparatus I (basket) with a rotation speed of 100 rpm and maintained at 37°C [3] .
Propranolol
Propranolol is a very effective and non-selective beta-adrenergic medicine which treats high blood pressure, angina (chest pain), irregular heartbeat, migraine headaches, and tremors. Propranolol is also used to improve survival after a heart attack (i.e. it lowers the risk of repeated heart attacks). It works by lowering the blood pressure by changing the transmission of nerve impulses from the brain to the certain part of the body and relaxes blood vessels, which decreases heart rate and pulse. Propranolol is categorized as a beta blockers medication. Beta blockers, which are also known as beta-adrenergic blocking agents, have a variety of usages like reducing blood pressure, and treating glaucoma and migraines. Beta blockers block the effects of the hormone epinephrine (adrenaline) that slows the heartbeat, reduces blood pressure, and improves blood flow [31] .
Propranolol is absorbed almost completely from the gastrointestinal tract after oral administration [32] , and because of hepatic first-pass effect, its bioavailability is extremely limited, about thirty percent. The hepatic first-pass effect is the drug absorption by the digestive system and entering the hepatic portal system after oral administration, and then goes through the portal vein into the liver. The metabolization of the liver causes only a portion of the drug to go through the circulation system. In other words, the bioavailability of the drug is reduced by liver [31] . To treat high blood pressure, the usual dose of propranolol is 120-240 mg divided in 2-3 doses per day; hence, there is a need to study the once-daily extended-release dosage formulation. Many studies had been reported with respect to controlled-release formulations, while none of them had focused on propranolol matrix ER formulations until Cheng et al. [3] developed an IVIVC model for propranolol matrix ER dosage formulations.
Objective
The objective of this thesis is to apply stochastic kriging with qualitative factors (SKQ)
proposed by Wang et al. [36] to model in-vivo and in-vitro data together for improved fitting of in-vivo behavior. The data used in this work are taken from Cheng et al. [3] .
SKQ is to utilize both in-vivo data, which are typically expensive and rare, and in-vitro data, which are usually less expensive and plentiful. By modeling both in-vivo and invitro data together, SKQ-fitted in-vivo profiles are of higher quality than those estimated from in-vivo data alone. Hence, SKQ renders the potential to save money and cost in invivo experiments.
Compared to IVIVC modeling pharmacology, SKQ has certain advantages. As mentioned before, in IVIVC modeling, the numerical deconvolution method is required as the first step. Numerical convolution method is also required as the last step of IVIVC modeling. Each of these steps introduces some additional errors to the model. Whereas, SKQ is free of these complicated convolution/deconvolution steps, and directly models in-vitro and in-vivo data.
The reminder of this thesis is organized as follows. Chapter 2 reviews the relevant literature. Chapter 3 describes the SKQ methodology. In chapter 4, simulation-based case studies are performed and illustrated the advantages of SKQ.
LITERATURE REVIEW
Previous IVIVC Studies
About half a century ago Levy et al. (1965) [4] , while working on aspirin tablets found out a substantial correlation between in-vitro dissolution and its in-vivo bioavailability.
They developed a single in-vitro dissolution rate test and figured out its correlation with the gastrointestinal absorption of aspirin from three different types of dosage forms.
Meanwhile, Wood [5] realized the same fact of high dependency between the drug absorption and dissolution rate. Wagner et al. [6] in 1973 asserted that there is a strong relationship between in-vitro and in-vivo data in an eight-subject two-way crossover study of different digoxin dosage forms. Lindenbaum et al. [7] , and Johnson et al. [8] in that year have done the same studies on relationships between in-vitro and in-vivo data of different digoxin dosage forms. After these discoveries, many studies were done about invitro in-vivo correlation (IVIVC) for different drugs and dosage forms. The studies were not limited to animals, such as rats and dogs, but they also included humans in their experiments [9] .
The differences in quality of various correlations led to the discovery of different levels of correlation between in-vitro and in-vivo patterns. In level A IVIVC, there is a strong correlation in many researches between dissolution data and drug absorption in the body.
The development and internally validation of an in-vitro in-vivo correlation for a hydrophilic matrix extended release metoprolol tablet was done by Eddington ND et al. [10] . A relationship discovered by Emami et al. [11] between in-vivo serum concentration profiles of the adopted sustained-release tablet of LC with a commercial one with the same characteristics in healthy subjects. Royce et al. [12] employed three distinct controlled release formulation principles in formulating 6-N-Cyclohexyl-2-Omethyladenosine to evaluate in-vitro dissolution, in-vivo absorption and their correlation.
On the other hand, many researches demonstrate less strong correlation between dissolution and absorption of a drug than level A, which are classified in Level B. El-Yazigi et al. [13] determined the dissolution rates of theophylline from six different commercially available products using the USP and rotating-filter dissolution apparatus to investigate the correlation between in-vitro parameters describing the dissolution characteristics of theophylline dosage forms and the in-vivo parameters. In another study, Dominguez et al. [14] evaluated the bioequivalence of three paracetamol tablets in twelve healthy volunteers using the American innovator product as the reference and they investigated the correlation between in-vitro mean dissolution time from dissolution profiles and in-vivo mean residence time from urinary excretion data.
The other category of a weaker correlation is Level C; such as the study of correlation between dissolution profiles of eleven different brands of phenytoin sodium capsules and observed differences in in-vivo parameters by Shah et al. [15] . In a different study, AlBehaisi et al. [16] established a linear relationship between logarithmic in-vivo blood sampling time and in-vitro dissolution time of deramciclane containing film-coated tablets assigned to equal cumulative area under the curve ratios.
Beside these three categories (levels A, B, and C), some IVIVCs belong to Multiple Level C, which is a powerful correlation and can be as good as Level A. Some studies that belong to this category are mentioned here. Volpato et al. [17] evaluated whether the new condition established by the US Pharmacopeia for the dissolution test would lead to a reasonable correlation between the bioavailability of the two levothyroxine formulations, and this study with levothyroxine tablets was performed on humans for the first time. Lin et al. [18] found the correlation between the in-vivo bioavailability of two different matrix-type aminophylline slow-release tablets in eight healthy male Chinese volunteers and in-vitro dissolution results by moment analysis. Despite the fact that many Level A correlation researches have been done, most of them do not provide appropriate predictability of the correlation assessment. A few numbers of reports include assessing and validation such as the study of correlation between in-vitro dissolution rate done in distilled water with the USP apparatus II and in-vivo after a single-dose administration in the morning by Humbert et al. [19] or the development of an in-vitro in-vivo correlation for two busprione hydrochloride extended-release formulations by Takka et al. [20] . In that study, the validation of IVIVC was determined using prediction errors for Cmax and AUC. Although the former was -0.16%, the latter was 16.1%, which is not acceptable since, based on FDA guidance for Industry Extended Release Oral Dosage Forms [1] , an average percent prediction error of less than 10% for bioavailability parameters is mandatory for all IVIVC studies to prove the reliability of the correlation.
IVIVC can also be used for application of a medicine or drug through the skin (transdermal delivery system) to correlate in-vitro skin permeation data to the in-vivo drug patterns. Qi et al. [21] utilize the convoluted in-vitro skin permeation data of a rabbit to predict the systemic drug concentration of 2,3,5,6-tetramethylpyrazine. The predicted concentrations were correlated well with the observed drug absorption profile. This result proved satisfactory in that the skin permeation tests predict the in-vivo drug profiles.
Fundamentals of the development of study design, lack of the appropriate dissolution design, and the difficulty in the measurement of the drug absorption can be different reasons which prohibit finding correlation between in-vivo parameters and in-vitro drug release data [9] . Siewert [22] classified the role of in-vitro dissolution tests in constructing an IVIVC at three different levels: selection of a drug product, definition of specific in-vitro test system, and provision of comprehensive data and derived parameters with respect to statistical aspects. Prasad et al. [23] show the importance of media selection in construction of IVIVC for quinidine gluconate. They demonstrate the dissolution rates of two different commercial formulations of controlled release 324 mg quinidine gluconate tablets were considerably diverse in water, phosphate buffer pH 5.4, and acetate buffer pH 5.4.
Kriging Models
Kriging includes a variety of Gaussian process-based modeling methods. Qian et al. [27] developed a general framework for deterministic kriging with qualitative factors, and an iterative estimation procedure for the model is developed. In 2009, a hierarchical Bayesian Gaussian process model was introduced by Han et al. [29] . The model considers both qualitative and quantitative factors assuming that the outputs relating to different levels of a qualitative factor are obtained from Gaussian stochastic processes with similar correlation structures. Zhou et al. [30] keep the flexibility of the unrestrictive correlation structure for qualitative factors introduced by Qian et al. [27] while trying to simplify their complex estimation process using the hypersphere parameterization to model the correlation of the qualitative factors. This method deals with standard nonlinear optimization problems with box constraints instead of optimization problems with positive definite constraints. All these methods are for deterministic data, and Wang et al. [36] proposed SKQ, which models stochastic data with both qualitative and quantitative factors. SKQ intends to pool information from all sources of data to obtain the models of the highest quality. The isotropic correlation function assumes that different levels of qualitative factor are of isotropic nature; it means, , is a constant number, exp{−∅}, for all ≠ .
Multiplicative correlation function (MC) is another correlation function for qualitative
factors that is similar to isotropic correlation functions except that MC assigns different correlation values to different pairs of qualitative factor levels, as one can recognize the difference in the formula which applied to our experiment as follows
In our case, because the qualitative factor has two levels, it is automatically of an exchangeable nature.
Let Σ be the × intrinsic variance-covariance matrix for the vector of averaged errors
includes n i replications at , = 1,2, … , k, assuming there are k design points. Σ can be specified by where |Σ| is the determinant of Σ which is equal to Σ M ( 2 , , Φ) + Σ ε , and ̃= ̅ − 
Simulation Model
The simulation model used to generate simulation data mimicking real experimental data from the study by Cheng et al. [3] , is described as follows Based on Wang et al. [36] , the true variance models utilized in the simulation model is described as follows For a subpopulation ( = 1,2) and at time 0 , a random response 0 is simulated as
where ε is a random error provided by a standard normal random generator. The true standard deviations used in the simulation model are plotted in Figure 4 . 
EMPIRICL RESULTS
In this thesis, two different cases are considered: deterministic and stochastic. In the former case, deterministic kriging is fitted to the expected values without considering any random errors. Deterministic kriging (DK) and deterministic kriging with qualitative factors (DKQ) are the two methods used in this section. In the latter case, stochastic, 6
replications for in-vitro data and 6 replications for in-vivo data are considered. Stochastic kriging (SK) and stochastic kriging with qualitative factors (SKQ) are the methods taken advantage of in the latter case.
Deterministic Case
It should be noted that in the deterministic approach the random error for the response has not been taken into account. As a result, if the same input is used in the model, the same response will be generated from the model. where Y(x, c q ), described in section 3.2, is the true expected value for subpopulation q at the abovementioned times. In-vitro and in-vivo expected values mimicking the real data from Cheng et al. [3] are presented in Table 1 and 2, respectively. Figure 5 shows the result of the DK implementation. In this figure, deterministic kriging is applied to the deterministic (without considering any random error) in-vivo and in-vitro data, separately.
Figure 3. Individual deterministic kriging on the data
Deterministic kriging with qualitative factors (DKQ) is applied to get a better fit. Figure 6 shows the plot of the DKQ implementation. In order to compare the result of in-vivo DK and DKQ, both of them are plotted in Figure  7 beside the in-vivo true response. As can be seen in the figure, the in-vivo DKQ plot is closer to the true response plot than the DK one. Besides comparing the result graphically in Figure 7 , the estimated root mean squared error can be used. It also helps to evaluate the accuracy of point estimate. To calculate ERMSE for in-vivo deterministic case, the total time range (from 0 to 24 hours) is divided into equally spaced, 0.2-hour, intervals. Therefore, a total number of 121 check points used to calculate the ERMSE, and consequently to evaluate the performances of DK and DKQ in predicting in-vivo response.
ERMSEs are calculated for both "deterministic kriging" and "deterministic kriging with qualitative factors" to compare the methods. ERMSE for DK is equal to 13.41, and the value for DKQ is 4.73. The comparison of these two numbers indicates that the fitted DKQ dominates DK in terms of predicting in-vivo response surface since SKQ has less deviation from the true response than SK.
Stochastic Case
In the real world, the availability of in-vivo data is scarce due to the expense and risks associated with data collection. On the other hand, in-vitro data, which attained much easier and cheaper, can help the fitting to get closer to the true responses.
In this thesis, the in-vitro data is the dissolution amount of propranolol hydrochloride extended-release at 9 equally spaced time points. In-vivo data is the plasma concentration of the observed propranolol from the extended-release (ER) tablets at 7 equally spaced time points. To simulate the data, 6 replications (explained in appendix B) have been As seen in Figure 8 , individual stochastic kriging does not work quite well. Therefore, a need exists to utilize the combined in-vitro and in-vivo data to get a better fit for in-vivo To apply SKQ to the aggregated data, the qualitative factor "study type" was defined;
"in-vitro" and "in-vivo" were considered as its two different qualitative factor levels.
Then, stochastic kriging with qualitative factors was applied to the standardized data. Figure 9 shows the result of this implementation.
Figure 7. Stochastic kriging with qualitative factors on ERS data
In order to compare the result of in-vivo SK and SKQ, both of them are plotted in Figure  10 beside the in-vivo true response. As can be seen in the figure, the in-vivo SKQ plot is closer to the true response plot than the SK one. 
Figure 8. The result of in-vivo SK and SKQ in compare to the in-vivo true response
Besides comparing the result graphically in Figure 10 , the estimated root mean squared error can be used. It also helps to evaluate the accuracy of point estimate.
where # [ ] is the number of all check points used. ERMSE measures the average deviation of predicted response from the true response.
To calculate ERMSE for in-vivo stochastic case, like the deterministic case, the total time range (from 0 to 24 hour) is divided into equally spaced, 0.2-hour, intervals. Therefore, a total number of 121 check points used to calculate the ERMSE, and consequently to evaluate the performances of SK and SKQ in predicting in-vivo response.
ERMSEs are calculated for 500 macro-replications of both "individual stochastic kriging" and "stochastic kriging with qualitative factors" to compare the results. Each macro-replication refers to the process of applying SK and SKQ on one randomly generated data-set for both in-vitro and in-vivo using simulation model described in section 3.2. Then ERMSE are calculated for the in-vivo result of each macro-replication. Figure 11 shows the box plot of the calculated ERMSE of the 500 macro-replications. The comparison of the two box plots in Figure 11 indicates that the fitted SKQ performs better than SK because SKQ has less deviation from the true response in all 500 macroreplications. It implies that taking advantage of in-vitro data gives a much better fit of invivo data than applying the model on in-vivo data alone. 
CONCLUSION
This thesis applies a metamodeling technique, kriging, to approximate the response of the pharmaceutical in-vivo data (propranolol plasma concentration after administrating oral extended-release formulations). The data was generated by simulation mimicking the real data. Deterministic and stochastic are the two cases that were studied in this thesis.
In the former case, the deterministic case, DK and DKQ were evaluated for the true expected responses. Based on calculated ERMSE, applying the DKQ on deterministic computer experiment provides the in-vivo response closer to the true response than applying DK.
In the latter case, the stochastic case, SK and SKQ were applied to the data considering random errors. SK lacks information pooling ability. Therefore, a separate response SK model is fitted for each data source. On the other hand, SKQ benefits its ability to exploit information from multiple data sources. Therefore, the prediction of in-vivo response can be substantially improved because SKQ allows for the borrowing information from invitro data.
The comparison of SKQ over SK using calculated ERMSE for 500 macro-replications, indicates SKQ gives better result. Consequently, this comparison implies that involving the in-vitro data in the modeling gives a closer fitted model to the true response.
For the future research, a need exists to perform design of experiment (DOE) for both invitro and in-vivo experiments to determine the design points and the number of replications for each of the points. Cheng et al. [3] determined the release characteristics of the propranolol ER tablets using the basket method of USP apparatus I. The temperature was maintained at 98.5
Fahrenheit where the propranolol tablets were kept in 900mL of gastric fluid. Samples were collected at different times during 24 hours in batch sizes of five milliliter at a rotation speed of 100 rpm. Ultraviolet spectrophotometry at 290 nm wavelength was used to determine the amount of drug dissolved. Figure 12 illustrates in-vitro dissolution profiles of propranolol hydrochloride. Most of the drug was dissolved after 12 hours. For instance, about eighty percent of ER tablet with a fast rate of release was dissolved after half a day and it was dissolved almost completely within 24 hours. taken into consideration as well to get a better model. The goal is pursued using stochastic kriging with qualitative factor proposed by Chen et al. [28] .
A.2. Empirical Result
In this thesis, Matlab was used for two different cases; Deterministic and Stochastic. In the first case, we consider the means as the only points available. Therefore this scenario also can be applied on an experiment without any replication. Individual kriging and kriging with qualitative factors are the two methods used in this section.
In the second case, stochastic, we considered 100 replications for in-vitro data and 6
replications for in-vivo data. Stochastic kriging (SK) and stochastic kriging with qualitative factors (SKQ) are the methods have been taken advantage of.
A.2.1. Deterministic Case
It should be noted that in the deterministic approach the random error for the response has not been taken into account. As a result, if the same input parameters are used in the model, the same response will be generated from the model in all repeated runs. Table 1 shows the data obtained from Cheng et al. [3] work. Deterministic kriging is applied on the data. Figure 13 shows the result of the implementation.
Figure 11. Individual deterministic kriging on ERS data
Deterministic kriging with qualitative factors is applied to get a better fit. Figure 14 shows the plot of the DKQ implementation.
Figure 12. Deterministic kriging with qualitative factors on ERS data
The estimated root mean squared error is calculated to evaluate the accuracy of point estimate. It also helps to compare the applied DK and DKQ. ERMSEs were calculated in 100 macro-replications for both "individual kriging" and "kriging with qualitative factors" to compare the methods. Figure 15 shows the deterministic in-vivo ERMSE box plot of ERS data.
Figure 13. ERMSE box plot of in-vivo deterministic kriging
A.2.2. Stochastic Case
In the real world, the availability of in-vivo data is scarce due to the expense and risks associated with data collection. However, since the in-vitro data are attained much easier and cheaper, a great number of these types of data are accessible. In this thesis, the in- After data from both categories, in-vitro and in-vivo, were combined, the quantitative factor, time (x), and the response (y) have been standardized by this formula separately data_std = data − min max − min
Stochastic kriging was applied on the standardized in-vitro and in-vivo data separately.
To apply the stochastic kriging on aggregated data, the qualitative factor "study type"
was defined. Hence "in-vitro" and "in-vivo" were considered as its two different qualitative factor levels. Stochastic kriging with qualitative factors was applied on the standardized data. Figure 20 shows an example of fitting stochastic kriging on ERS data. As in figure 16 , individual stochastic kriging does not work quite well in many iterations. So a need is felt to utilize the combined in-vitro and in-vivo data to get a better fit.
Figure 14. Individual stochastic kriging on ERS data
was defined. Hence "in-vitro" and "in-vivo" were considered as its two different Figure 17 shows an example of this implementation.
Figure 15. An example of applied SKQ on ERS data
As done in previous section, Deterministic, ERMSEs were calculated in 100 macroreplications for both "individual stochastic kriging" and "stochastic kriging with qualitative factors" to compare them. Figure 18 shows the ERMSE box plot of in-vivo stochastic kriging. 
B.2. In-vivo
The desired half-with for in-vivo at = 4.3ℎ is considered as = [5 , 8] . A sample of size 0 = 6 is drawn and α is considered as 5%. 
